欧林生物(688319) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥70,798,700.81, representing a year-on-year increase of 5.87%[5]. - The net profit attributable to shareholders was a loss of ¥25,996,930.16, a decrease of 774.61% compared to the same period last year[5]. - The basic earnings per share (EPS) for the period was -¥0.0641, reflecting a decline of 774.74% compared to the previous year[5][6]. - The company reported a net loss of CNY 28,310,589.67 for Q1 2024, a decline from a profit of CNY 3,798,251.05 in Q1 2023[17]. - The total net profit for Q1 2024 was -27,295,829.82 RMB, compared to a net profit of 2,348,538.26 RMB in Q1 2023, indicating a significant decline[18]. - The basic and diluted earnings per share for Q1 2024 were both -0.0641 RMB, down from 0.0095 RMB in the same period last year[19]. - The total comprehensive income for Q1 2024 was -27,295,829.82 RMB, down from 2,348,538.26 RMB in Q1 2023[19]. Research and Development - Research and development (R&D) expenses totaled ¥62,139,896.94, an increase of 146.26% year-on-year, accounting for 87.77% of operating revenue, up from 50.04%[6][8]. - R&D expenses surged to CNY 47,738,722.74 in Q1 2024, compared to CNY 18,648,503.13 in Q1 2023, marking an increase of 156.5%[17]. - The company is focusing on the development of new technologies, including a quadrivalent influenza vaccine and AC combined vaccine clinical trials[8]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,594,137,275.99, a decrease of 1.15% from the end of the previous year[6]. - Total assets decreased to CNY 1,594,137,275.99 as of March 31, 2024, down from CNY 1,612,605,765.09 at the end of 2023[15]. - Total liabilities increased slightly to CNY 686,446,174.11 as of March 31, 2024, compared to CNY 681,840,228.71 at the end of 2023[15]. - The company’s equity attributable to shareholders decreased to CNY 895,130,016.80 as of March 31, 2024, down from CNY 916,905,551.64 at the end of 2023[15]. - Non-current assets totaled CNY 709,913,157.08 as of March 31, 2024, an increase from CNY 681,416,011.50 at the end of 2023[14]. Cash Flow - Cash flow from operating activities for Q1 2024 was -65,394,362.43 RMB, compared to -33,277,917.58 RMB in Q1 2023, reflecting worsening cash flow performance[20]. - The company reported a decrease in cash received from operating activities, totaling 91,177,236.11 RMB in Q1 2024, compared to 109,853,310.29 RMB in Q1 2023[20]. - Cash inflow from investment activities was 10,018,657.53 RMB in Q1 2024, a decrease from 90,644,728.77 RMB in Q1 2023[20]. - Cash outflow from investment activities increased to 77,328,580.10 RMB in Q1 2024, compared to 21,109,092.44 RMB in Q1 2023[20]. - Cash flow from financing activities showed a net increase of 63,953,060.05 RMB in Q1 2024, compared to a net decrease of -6,005,425.90 RMB in Q1 2023[21]. - The company received 67,773,800.00 RMB in borrowings during Q1 2024, an increase from 45,000,000.00 RMB in Q1 2023[21]. - Cash and cash equivalents decreased to CNY 293,322,800.83 as of March 31, 2024, down from CNY 362,070,721.55 at the end of 2023, a reduction of 19.0%[13]. - The company reported cash and cash equivalents at the end of Q1 2024 amounting to 286,783,648.23 RMB, slightly down from 291,362,822.86 RMB at the end of Q1 2023[21]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 8,210[10]. - The top shareholder, Chongqing Wushan Biotechnology Co., Ltd., held 72,394,330 shares, accounting for 17.82% of total shares[10].